9 results on '"Fox, M"'
Search Results
2. To be, or not to be, a non-native freshwater fish?
- Author
-
Copp, G. H., Bianco, P. G., Bogutskaya, N. G., Erős, T., Falka, I., Ferreira, M. T., Fox, M. G., Freyhof, J., Gozlan, R. E., Grabowska, J., Kovéč, V., Moreno-Amich, R., Naseka, A. M., Peňáz, M., Povž, M., Przybylski, M., Robillard, M., Russell, I. C., Stakėnas, S., and Šumer, S.
- Subjects
FRESHWATER fishes ,BIOGEOGRAPHY ,ANIMAL dispersal ,GOBIIDAE - Abstract
We examine the evolving concept of what constitutes a non-native (or alien) freshwater fish. In an attempt to distinguish between biogeographical and socio-political perspectives, we review the patterns in the introduction and dispersal of non-native fishes in Europe and North America, and especially the recent expansion of Ponto-Caspian gobies in Europe. We assess patterns in the development of national policy and legislation in response to the perceived threat of non-native fish introductions to native species and ecosystems. We review, and provide a glossary of, the terms and definitions associated with non-native species. Finally, we discuss perspectives as regards the future treatment of naturalized species. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
3. Development of a Multinational Clinical Practice Guideline: A Practical Structured Procedure.
- Author
-
Sonyi M, Keller J, Fox M, and Hammer HF
- Subjects
- Europe, Humans, Practice Guidelines as Topic
- Abstract
Introduction: The development of a clinical guideline is a challenging process. National and international organizations have established a variety of approaches, grading systems, evaluation scales, and voting modes; however, a practical description which illustrates all steps from starting the initiative to publication and dissemination of the guideline is usually not provided. We describe a structured guideline procedure that can be adjusted to the requirements of other multinational guidelines., Methods: A group of European specialist gastroenterological societies and national societies initiated a guideline for the use of breath tests in gastroenterology. A balance between scientific evidence and clinical experience was achieved by involving European specialist societies and physicians from 18 European countries. For persons contributing to the guideline process, different levels of involvement were defined. The tasks were assigned to different groups of persons, which formed scientific institutions., Results: We describe organizational structures and institutions, the stepwise approach, and illustrate the multistep guideline development procedure in a flowchart diagram that shows workflow and assigned responsibilities and provides details for the execution of each step, including timelines. The process is split into 4 phases: foundation, preparation, voting, and publication., Discussion: This structured procedure of a gastroenterological clinical practice guideline can serve as a blueprint for future multinational guideline initiatives and may aid future attempts to standardize and harmonize guideline development processes in gastroenterology and in other medical fields. Although the described procedure is for a diagnostic guideline, it may also be appropriate for therapeutic guidelines by adjusting the acceptance criteria for recommendations., (© 2020 S. Karger AG, Basel.)
- Published
- 2021
- Full Text
- View/download PDF
4. Can initial vaginal bleeding patterns in etonogestrel implant users predict subsequent bleeding in the first 2 years of use?
- Author
-
Mansour D, Fraser IS, Edelman A, Vieira CS, Kaunitz AM, Korver T, Pong A, Lin J, Shah AK, Fox M, Rekers H, and Creinin MD
- Subjects
- Adult, Chile, Europe, Female, Humans, Time Factors, United States, Young Adult, Amenorrhea chemically induced, Contraceptive Agents, Female adverse effects, Desogestrel adverse effects, Drug Implants adverse effects, Menstruation drug effects
- Abstract
Objectives: To evaluate if a simple method for characterizing vaginal bleeding patterns in etonogestrel contraceptive implant users can predict subsequent patterns and bleeding-related discontinuation over the first 2 years of use., Study Design: We reanalyzed phase 3 study bleeding data for non-breastfeeding participants from the United States, Europe, Russia and Chile during the first 2 years of implant use to characterize and correlate bleeding patterns. We used 90-day reference periods with period 1.1 starting at Day 29 and ending at Day 118. We dichotomized bleeding patterns as "favorable" (amenorrhea, infrequent bleeding and normal frequency bleeding without prolonged bleeding) or "unfavorable' (prolonged and/or frequent bleeding) and tracked user groups based on these bleeding patterns in reference period 1.1 through Year 1 and from Year 1 through Year 2, respectively., Results: We evaluated data from 537 and 428 women with up to 1 and 2 years use, respectively. Of the 325 (60.5%) women with favorable bleeding in reference period 1.1, 275 (84.6%) reported favorable bleeding also in reference period 2, 197 (60.6%) reported favorable bleeding throughout Year 1, and favorable bleeding in 75-85% of reference periods in Year 2. Among 212 (39.5%) women with unfavorable bleeding in reference period 1.1, 118 (55.7%) continued with unfavorable bleeding in reference period 2, while about 40%-50% reported favorable patterns in RP 2, 3 and/or 4. Initial favorable bleeding resulted in lower discontinuation rates than initial unfavorable bleeding in years 1 (3.7% vs 12.7%, p≪.0001) and 2 (2.5% vs 16.5%, p≪.0001)., Conclusion: Implant users with favorable bleeding in the first reference period are likely to continue with favorable bleeding over the next 2 years. Initial bleeding patterns predict overall continuation rates in years 1 and 2. Implications Statement When evaluating vaginal bleeding in any 90-day reference period over 2 years of etonogestrel implant use, approximately 80% of women with favorable and 40% with unfavorable bleeding patterns will have favorable bleeding in the next reference periods. These findings can facilitate counseling regarding bleeding for women using the etonogestrel implant., (Crown Copyright © 2019. Published by Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
5. Mortality in patients with HIV-1 infection starting antiretroviral therapy in South Africa, Europe, or North America: a collaborative analysis of prospective studies.
- Author
-
Boulle A, Schomaker M, May MT, Hogg RS, Shepherd BE, Monge S, Keiser O, Lampe FC, Giddy J, Ndirangu J, Garone D, Fox M, Ingle SM, Reiss P, Dabis F, Costagliola D, Castagna A, Ehren K, Campbell C, Gill MJ, Saag M, Justice AC, Guest J, Crane HM, Egger M, and Sterne JA
- Subjects
- Adult, Anti-HIV Agents therapeutic use, Cohort Studies, Europe epidemiology, Female, Follow-Up Studies, Humans, Male, Middle Aged, Mortality trends, North America epidemiology, Prospective Studies, South Africa epidemiology, Antiretroviral Therapy, Highly Active mortality, Antiretroviral Therapy, Highly Active trends, Cooperative Behavior, HIV Infections drug therapy, HIV Infections mortality, HIV-1
- Abstract
Background: High early mortality in patients with HIV-1 starting antiretroviral therapy (ART) in sub-Saharan Africa, compared to Europe and North America, is well documented. Longer-term comparisons between settings have been limited by poor ascertainment of mortality in high burden African settings. This study aimed to compare mortality up to four years on ART between South Africa, Europe, and North America., Methods and Findings: Data from four South African cohorts in which patients lost to follow-up (LTF) could be linked to the national population register to determine vital status were combined with data from Europe and North America. Cumulative mortality, crude and adjusted (for characteristics at ART initiation) mortality rate ratios (relative to South Africa), and predicted mortality rates were described by region at 0-3, 3-6, 6-12, 12-24, and 24-48 months on ART for the period 2001-2010. Of the adults included (30,467 [South Africa], 29,727 [Europe], and 7,160 [North America]), 20,306 (67%), 9,961 (34%), and 824 (12%) were women. Patients began treatment with markedly more advanced disease in South Africa (median CD4 count 102, 213, and 172 cells/µl in South Africa, Europe, and North America, respectively). High early mortality after starting ART in South Africa occurred mainly in patients starting ART with CD4 count <50 cells/µl. Cumulative mortality at 4 years was 16.6%, 4.7%, and 15.3% in South Africa, Europe, and North America, respectively. Mortality was initially much lower in Europe and North America than South Africa, but the differences were reduced or reversed (North America) at longer durations on ART (adjusted rate ratios 0.46, 95% CI 0.37-0.58, and 1.62, 95% CI 1.27-2.05 between 24 and 48 months on ART comparing Europe and North America to South Africa). While bias due to under-ascertainment of mortality was minimised through death registry linkage, residual bias could still be present due to differing approaches to and frequency of linkage., Conclusions: After accounting for under-ascertainment of mortality, with increasing duration on ART, the mortality rate on HIV treatment in South Africa declines to levels comparable to or below those described in participating North American cohorts, while substantially narrowing the differential with the European cohorts. Please see later in the article for the Editors' Summary.
- Published
- 2014
- Full Text
- View/download PDF
6. The impact of double-blind placebo- controlled food challenge (DBPCFC) on the socioeconomic cost of food allergy in Europe.
- Author
-
Cerecedo I, Zamora J, Fox M, Voordouw J, Plana N, Rokicka E, Fernandez-Rivas M, Vázquez Cortés S, Reche M, Fiandor A, Kowalski M, Antonides G, Mugford M, Frewer LJ, and De la Hoz B
- Subjects
- Adult, Child, Preschool, Costs and Cost Analysis, Double-Blind Method, Europe, Female, Humans, Longitudinal Studies, Male, Prospective Studies, Cost of Illness, Food Hypersensitivity diagnosis, Food Hypersensitivity economics
- Abstract
Background: Double-blind placebo controlled food challenge (DBPCFC) is the gold standard diagnostic test in food allergy because it minimizes diagnostic bias., Objective: To investigate the potential effect of diagnosis on the socioeconomic costs of food allergy., Methods: A prospective longitudinal cost analysis study was conducted in Spain and Poland within the EuroPrevall project. Food-allergic patients were enrolled into the study and in all cases diagnosis was confirmed through a standardized DBPCFC. Data were collected through a self-administered survey on all aspects of health and social care resource use, costs of living, and costs of leisure activities. Costs were measured before and 6 months after the DBPCFC and reported in international dollars with 2007 as the benchmark year., Results: Forty-two patients were enrolled. Twenty-one patients had a negative DBPCFC and the suspected food was reintroduced into their diet. Comparing total direct costs before and after the DBPCFC, the reactive group spent a significantly higher amount (median increase of $813.1 over baseline), while the tolerant group's spending decreased by a median of $87.3 (P = .031). The amount of money spent on food 6 months after diagnosis was also significantly higher in the reactive group (P = .040). Finally, a larger, but not statistically significant, decrease in total indirect costs was observed in the tolerant group compared with the reactive group ($538.3 vs $32.3)., Conclusion: DBPCFC has an impact on indirect and direct costs of living. The main contribution to this increase was money spent on food.
- Published
- 2014
7. Health sector costs of self-reported food allergy in Europe: a patient-based cost of illness study.
- Author
-
Fox M, Mugford M, Voordouw J, Cornelisse-Vermaat J, Antonides G, de la Hoz Caballer B, Cerecedo I, Zamora J, Rokicka E, Jewczak M, Clark AB, Kowalski ML, Papadopoulos N, Knulst AC, Seneviratne S, Belohlavkova S, Asero R, de Blay F, Purohit A, Clausen M, Flokstra de Blok B, Dubois AE, Fernandez-Rivas M, Burney P, Frewer LJ, and Mills CE
- Subjects
- Adult, Case-Control Studies, Child, Cost of Illness, Europe epidemiology, Female, Health Expenditures, Humans, Immunoglobulin E adverse effects, Male, Middle Aged, Regression Analysis, Self Report, Severity of Illness Index, Socioeconomic Factors, Surveys and Questionnaires, Young Adult, Food Hypersensitivity economics, Health Care Costs statistics & numerical data, Public Health economics
- Abstract
Introduction: Food allergy is a recognized health problem, but little has been reported on its cost for health services. The EuroPrevall project was a European study investigating the patterns, prevalence and socio-economic cost of food allergy., Aims: To investigate the health service cost for food-allergic Europeans and the relationship between severity and cost of illness., Methods: Participants recruited through EuroPrevall studies in a case-control study in four countries, and cases only in five countries, completed a validated economics questionnaire. Individuals with possible food allergy were identified by clinical history, and those with food-specific immunoglobulin E were defined as having probable allergy. Data on resource use were used to estimate total health care costs of illness. Mean costs were compared in the case-control cohorts. Regression analysis was conducted on cases from all 9 countries to assess impact of country, severity and age group., Results: Food-allergic individuals had higher health care costs than controls. The mean annual cost of health care was international dollars (I$)2016 for food-allergic adults and I$1089 for controls, a difference of I$927 (95% confidence interval I$324-I$1530). A similar result was found for adults in each country, and for children, and was not sensitive to baseline demographic differences. Cost was significantly related to severity of illness in cases in nine countries., Conclusions: Food allergy is associated with higher health care costs. Severity of allergic symptoms is a key explanatory factor.
- Published
- 2013
- Full Text
- View/download PDF
8. Social and economic costs of food allergies in Europe: development of a questionnaire to measure costs and health utility.
- Author
-
Fox M, Voordouw J, Mugford M, Cornelisse J, Antonides G, and Frewer L
- Subjects
- Chronic Disease, Europe epidemiology, Focus Groups, Humans, Incidence, Pilot Projects, Prevalence, Severity of Illness Index, Transportation, Cost of Illness, Food Hypersensitivity economics, Research Design, Surveys and Questionnaires
- Abstract
Objectives: To develop a questionnaire to measure the additional social costs of food allergies (FAs). DATA SOURCE AND STUDY SETTING: People with FAs and sampled members of the general population (with and without FAs) in the Netherlands and the United Kingdom in 2006., Study Design: (1) Literature review. (2) Focus group to identify key costs of FAs and seek views on the questionnaires. (3) Pilot survey to test the questionnaires in cases and controls., Data Collection: Twenty-eight participants in the United Kingdom and the Netherlands with clinically or self-diagnosed FAs took part in one of five focus groups. A case-control postal survey was conducted in the United Kingdom and the Netherlands (with 125 FA cases and 62 controls)., Principal Findings: Methods exist to measure social costs in chronic illness, but not FAs. Focus groups found features of FAs likely to impact costs of living. Pilot results suggest higher costs of living and health care costs, and well-being in FAs., Conclusion: The questionnaire is proposed for use in wider European and other comparative studies of FAs.
- Published
- 2009
- Full Text
- View/download PDF
9. The veterinarian and farm animal welfare.
- Author
-
Fox MW
- Subjects
- Animals, Europe, Housing, Animal, United States, Animal Husbandry, Ethics, Veterinary Medicine
- Published
- 1980
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.